BMJ Mental Health

Introduction: Parkinson's disease is a neurodegenerative disease affecting motor and cognitive function that has a major impact on society. Epidemiological evidence has suggested that the incidence of PD may be increasing; however, the underlying etiology is unclear. Here, we investigated the role of increasingly used antipsychotics in the diagnosis of PD. Methods: We harnessed Merative Marketscan insurance claims databases to conduct a case-control study of 65,275 new cases of PD and 652,364 age-, sex-, and time-matched controls. We estimated associations between exposure and duration of use for antipsychotics adjusted for important confounders using fixed effects logistic regression. We performed sensitivity analyses stratified by the level of D2 receptor inhibition to assess dose-response relationships; a lagged exposure analysis to address confounding by indication; analysis assessing exposure of other psychiatric medications without significant D2 inhibition (bupropion, trazodone, and Z-drugs); analysis assessing exposure of non-psychiatric medications with significant (metoclopramide) or no D2 inhibition (ondansetron). Results: We found cases with PD had elevated odds of antipsychotic exposure. Longer durations of exposure and greater affinity for the D2 receptor were associated with greater associations with PD. There was a dose-response relationship between D2 inhibition activity and increased odds of PD for a similar duration of exposure. There was a dose response relationship between duration of metoclopramide and the odds of PD; however, there was no such relationship between the non-D2 inhibiting control medications. The association between exposure to an antipsychotic and increased odds of PD was present even when the first exposure was 10 years prior to the PD diagnosis date. Conclusion: If these results are causal, antipsychotic use may explain up to 2.4% of all cases of PD. Given the increasing rate of use of these medications, and the concurrent increasing age-adjusted incidence of PD, there is an urgent need for further investigation into this association and greater awareness of the potential risks of these medications in older adults.

Living at risk of a neurodegenerative condition such as inherited prion disease (IPD) is associated with substantial psychological burden, yet evidence-based supportive interventions are lacking. This unmet need is likely to grow as advances in biomarkers and predictive testing lead to increasing identification of individuals in pre-symptomatic stages of neurodegenerative disease. Acceptance and Commitment Therapy (ACT), a transdiagnostic intervention targeting psychological flexibility, has shown promise in chronic health contexts but has not been evaluated in individuals at genetic risk. We conducted a feasibility and acceptability study of a brief, group-based ACT intervention in adults at risk of IPD recruited through the UK National Prion Clinic. The intervention comprised a single 5-hour, face-to-face workshop followed by an individual booster session. Prespecified feasibility and acceptability criteria were assessed alongside secondary psychological outcomes at baseline, 1 month, and 3 months post-intervention, complemented by semi-structured qualitative interviews. Twenty-three participants completed the intervention. All predefined feasibility criteria were met, including recruitment (58%), intervention completion (80%), retention at 3 months (79%), and low missing data (10%). Acceptability was high, with all participants reporting the intervention as useful and appropriate. Quantitative analyses demonstrated improvements in psychological quality of life and behavioural awareness at 3 months, with larger effects observed in participants with elevated baseline depressive symptoms. Qualitative findings highlighted the importance of peer connection, experiential learning, and practical strategies for managing uncertainty. These findings demonstrate that a brief, hybrid ACT intervention is feasible and acceptable for individuals living at risk of IPD and provide preliminary evidence for improving psychological well-being. As the population of individuals identified as at risk for neurodegenerative disease continues to expand, scalable psychological interventions that address cost and time barriers may represent an important component of future clinical care.

Lithium has been the gold standard for the treatment and prevention of relapse in bipolar disorder for over 60 years. Guidance from the National Institute for Health and Clinical Excellence states explicitly to 'offer lithium as a first-line, long-term pharmacological treatment for bipolar disorder'. Yet, in the last two decades its use has been in decline with clinicians favouring anticonvulsants or antipsychotics when treating this condition. In this study, we have used three openly available datasets containing prescribing data from primary and secondary care to explore trends in the use of lithium in England, showing both regional and temporal variance between 2015-2024. We have shown that lithium use declined in primary care by 20.9% in the last ten years (2015-2024) and 10.9% overall in the last five years (2019 to 2025). We have also shown how there is some regional variation in the source of lithium for patients, although the vast majority is prescribed in primary care. Further research into clinical behaviour is needed to understand what is driving the decrease in lithium usage, and what barriers and enablers may influence its use across the country.

Background For people with bipolar disorder, recovery from manic or mixed episodes is frequently complicated by depression. Depression after manic/mixed episodes may occur within a broader episode sequence pattern of mania-depression-euthymic interval, proposed as a bipolar disorder subtype for which lithium is effective. However, the window of risk for mania/mixed-to-depression transition remains unclear, as is the relationship with clinical factors and outcomes. Methods In this retrospective cohort study, we identified a cohort of 10,437 people with bipolar disorder (42,314 mood episodes; 90,727 person-years) within the NeuroBlu health record database (United States) with records from 1959 to 2025. We quantified the transition time from manic/mixed episodes to depression, and investigated associations with clinical features, medications and outcomes. Outcomes 25% of all manic episodes and 22% of all mixed episodes transitioned to depression within 1 month: an incidence >11-times higher than the overall per-month depression rate. By 6 months, the depression transition rate had plateaued. Short depression transition time ([≤]1 month) was associated with previous short transition times (post-mania RR=3.08, 95%CI: 2.65-3.58; post-mixed RR=2.52, 95%CI: 2.12-3.00), higher manic/mixed severity (post-mania RR=1.30 per 1 point CGI-S increase, 95%CI: 1.18-1.44; post-mixed RR=1.35, 95%CI: 1.15-1.57) and hospitalisation for the mania/mixed episode (post-mania RR=1.22, 95%CI: 1.09-1.37; post-mixed RR=1.71, 95%CI: 1.52-1.94). Among medications prescribed during hospital-associated manic/mixed episodes, lithium (post-mania RR=0.75, 95%CI: 0.62-0.91; post-mixed RR=0.72, 95%CI: 0.54-0.95), first-generation sedating antihistamines (post-mania: RR=0.74, 95%CI: 0.63-0.87) and other mood stabilisers (post-mania RR=0.82, 95%CI: 0.71-0.94, post-mixed RR=0.82, 95%CI: 0.72-0.94) were associated with longer transition time. Antipsychotics, antidepressants and benzodiazepines were not. Shorter transition time was associated with more depression-related hospital days (16% fewer days per month delay to depression, 95%CI: 4-25%, p=0.010). Interpretation It is important to monitor for depression soon after manic/mixed episodes. This depression may be predictable, and might be preventable with some medications prescribed during the manic/mixed episode.

Background: Long COVID is a syndrome characterized by symptoms and conditions across all biological systems. This breadth of Long COVID phenotypes impedes efforts to identify the mechanistic pathways of Long COVID. Low serotonin may play a role in long-term sequelae of COVID-19, and selective serotonin reuptake inhibitors (SSRIs) may prevent these sequelae. Evaluation of the relationship between SSRIs and distinct categories of symptoms and conditions associated with Long COVID can highlight the mechanistic pathways that drive these relationships. Methods: We evaluated electronic health record data from a retrospective cohort of patients in the National Clinical Cohort Collaborative with comorbid depression and COVID-19 between October 2021 and February 2024. We estimated the relationship between SSRI prescription (versus no SSRI prescription) during acute COVID-19 and the one-year cumulative incidence of Long COVID-related conditions and symptoms across 14 human phenotype ontology categories. We applied Super Learner and targeted maximum likelihood estimation to estimate risk ratios while adjusting for confounders of interest and correcting for false discoveries from repeated testing. Results: We evaluated EHR data from 542,938 patients. We found that patients who were prescribed SSRIs during COVID-19 had a significantly lower risk of symptoms and conditions related to gastrointestinal factors (adjusted risk ratio (aRR) 0.95, 95% CI 0.92, 0.97), general health (aRR 0.91, 95% CI 0.88, 0.95), headaches (aRR 0.96, 95% CI 0.92, 0.99) and skin (aRR 0.92, 95% CI 0.87, 0.98). Discussion: We found that the prescription of SSRIs during acute COVID-19 was associated with a significantly lower risk of post-COVID sequelae related to gastrointestinal, headache-related, skin-related, and general symptoms and conditions, compared with no SSRI prescription. These findings highlight the role of serotonin in Long COVID and specific sequelae that may be reduced by SSRIs.

Objective: To compare first-line emergency department (ED) treatment classes for acute headache on short-term all-cause ED return and index admission across two independent health systems. Background: ED trials of acute headache treatment are judged on in-ED pain relief, a documented endpoint that is recorded incompletely and shifts with the scoring rule, and is a weak surrogate for what happens after discharge. All-cause ED return after an index headache visit (any subsequent ED encounter within the window) has not been used to compare first-line treatments at scale, and society guidance favors dopamine-receptor antagonists while recommending against routine opioids. Methods: Retrospective two-center cohort of adults treated for headache in the ED, using MIMIC-IV-ED (Beth Israel Deaconess Medical Center, 2011-2019) and MC-MED (Stanford, 2020-2022). The first-line class was the earliest qualifying acute agent. The primary contrast was opioids versus dopamine-receptor antagonists (the guideline-preferred class). Outcomes were 72-hour and 7-day all-cause ED return (among discharged patients; any subsequent ED encounter within the window) and index hospital admission. Confounding by indication was addressed with propensity overlap weighting; associations are reported as adjusted risk ratios (RRs) with bootstrap 95% CIs and E-values. Estimates were pooled with a site term and examined per site. Results: Among 13,285 treated adults (10,799 MIMIC-IV-ED; 2,486 MC-MED), opioid recipients were older and higher-acuity than dopamine-antagonist recipients (index admission 38.1% vs 16.4%). In the MIMIC-IV-ED discharged primary-contrast population, overlap weighting reduced the maximum standardized mean difference from 0.35 to 0.002; pooled and site-specific balance diagnostics are provided in the Supplement. First-line opioids remained associated with a higher 72-hour all-cause ED return (6.8% vs 3.8%; adjusted RR 1.79; 95% CI 1.31 to 2.33), 7-day return (10.7% vs 6.6%; RR 1.62; 95% CI 1.28 to 1.98), and index admission (RR 2.32; 95% CI 2.11 to 2.58, consistent with strong residual severity differences in patients selected for opioids). The direction of association was concordant across both health systems, although MC-MED return estimates were imprecise given the smaller opioid-treated discharged sample. In MIMIC-IV-ED, the cumulative all-cause return incidence by treatment class separated by day 3 and persisted through 30 days. The direction was consistent, though attenuated and no longer statistically significant, when the outcome was restricted to a headache-specific return (72-hour RR 1.31; 95% CI 0.91 to 1.88); the direction persisted for the composite of admission or 72-hour return, which does not condition on discharge but is influenced by the more confounded admission component (RR 2.16; 95% CI 1.98 to 2.39). Conclusion: Across two health systems, first-line opioid treatment for ED headache was associated with higher all-cause short-term ED return among discharged patients and higher index admission than dopamine antagonists. These observational associations reflect downstream all-cause ED utilization after an index headache visit rather than confirmed headache recurrence or treatment failure; they are consistent with guideline-concordant, opioid-sparing first-line treatment and warrant prospective confirmation. Plain Language Summary: Emergency departments treat headaches with several different medicines, but the usual way of judging which works, the pain score recorded during the visit, is often missing or inconsistent. Using two large hospital systems and a clearer outcome, whether patients came back to the emergency department for any reason, we found that patients first treated with opioids returned within 72 hours about 1.8 times as often as those given the guideline-preferred dopamine-blocking medicines and were admitted more than twice as often. These patterns pointed the same direction in both hospital systems after adjustment for the measured differences available in both databases. Because this was an observational comparison and returns were counted for any reason, the findings are consistent with using guideline-preferred non-opioid medicines first, rather than proof that opioids worsen headache.

Persons with epilepsy (PWE) experience high rates of psychiatric comorbidity, yet the population-scale pharmacoepidemiology of psychiatric medication (PM) use alongside antiseizure medications (ASMs) has not been previously characterized. Using Epic Cosmos, a federated electronic health record network spanning >300 million patients across >2,000 hospital systems, we examined patterns of ASM and PM co-prescriptions in PWE (ICD- 10 G40.x) every year between 2018-2025. PM prescriptions were similarly assessed in patients with asthma (J45.x). We found that despite the introduction of several newer ASMs, the overall prescribing landscape remained stable, with little change in the relative use of individual ASMs over time. Compared with asthma patients, PWE were more likely to receive prescriptions for opiates, antidepressant and antipsychotic medications across the age spectrum. 17-year-old or younger PWE were more likely to receive ADHD/stimulant medications, whereas adults and older adults exhibited a shift toward cognitive enhancing agents. We did not observe a preponderance of PM co- prescribing with any specific ASM or ASM class. Together, these results provide a population-scale, age-specific survey of psychiatric medication co-prescriptions in epilepsy, establishing a framework to monitor surrogate markers of psychiatric comorbidity and to support pharmacovigilance of potential drug-drug interactions.

Importance: Patients who achieve remission from major depressive disorder (MDD) often face a preference-sensitive decision between continued antidepressant maintenance and discontinuation with active monitoring. Quantifying the tradeoff between depression burden and long-term medication exposure may support more individualized shared decision-making. Objective: To quantify tradeoffs between continuous antidepressant maintenance and active monitoring after MDD remission, and to identify preference thresholds favoring each strategy across relapse-risk strata. Design: Individual-level decision-analytic health-state transition model calibrated to randomized maintenance-discontinuation trials and a longitudinal first depressive episode cohort, with a 5-year time horizon. Setting: Outpatient clinical decision after completion of an 8-month continuation phase following remission from MDD. Participants: Adults in remission from MDD, represented across 4 clinically anchored relapse-risk strata ranging from very low risk after a first mild episode to high risk after highly recurrent depression. Exposures: Continuous antidepressant maintenance vs discontinuation with active monitoring and antidepressant restart after detected relapse. Main Outcomes and Measures: Severity-weighted depression-months, antidepressant medication-years, medication-years per depression-month averted, and net benefit across preference thresholds defined as the maximum additional medication-years a patient would be willing to accept to avert 1 depression-month. Results: Continuous maintenance reduced depression burden but required substantially more medication exposure, with efficiency strongly dependent on relapse risk. Medication-years per depression-month averted ranged from 11.8 (95% uncertainty interval [UI], 7.8-19.6) in the very low-risk group to 1.5 (95% UI, 0.8-3.0) in the high-risk group. At a preference threshold of 3 medication-years per depression-month averted, maintenance was preferred for moderate- and high-risk patients; at a threshold of 2, only for high-risk patients; and at a threshold of 1, for no risk group. Conclusions and Relevance: In this decision-analytic model, the value of continuous antidepressant maintenance depended strongly on baseline relapse risk and patient preferences regarding long-term medication exposure. These findings provide a quantitative framework for shared decision-making about antidepressant maintenance after remission from MDD.

Objective: Sleep health and depression are interconnected multidimensional constructs, yet their shared determinants remain obscure. Understanding the role of socioeconomic/lifestyle factors in predicting sleep-related depression (SRD) is critical for preventive strategies. This study aimed to identify the key socioeconomic/lifestyle predictors of SRD in the general population and patients with clinical depression. Methods: To characterize SRD, we performed regularized canonical correlation analysis between sleep and depression to identify latent phenotypes of SRD in a general population subsample (GP1; n=87,405) from the UK Biobank. Subsequently, machine-learning predictive models were developed in GP1 to predict SRD using socioeconomic/lifestyle factors. The best-performing predictive model was subsequently validated in GP2 at both baseline and follow-up (GP2; n=5,187), and in clinical depression (n=7,454) to assess its generalizability. Complementary analyses were conducted to assess other latent phenotypes (i.e., depression-related sleep, non-SRD, non-depression-related sleep, overall sleep health, and overall depression). Results: A robust multivariate association was identified between sleep and depression in GP1 (canonical r = 0.42, PFDR < 0.001). Socioeconomic/lifestyle factors moderately predicted SRD (r = 0.25; 95% CI: [0.24, 0.25]; R2 = 0.06; 95% CI: [0.06, 0.06]; rMSE = 1.08; 95% CI: [1.08, 1.09]). The top predictors were less frequency of confiding in others, more sedentary television viewing, less vigorous physical activity, and passive smoking exposure. Out-of-sample validation of the predictive model showed similar patterns in GP2 at baseline, at follow-up, and in clinical depression subsamples. Similarly, less frequency of confiding in others and greater sedentary television viewing were the main predictors of other depression-related profiles, whereas more alcohol consumption frequency, less walking frequency, and less time spent outdoors in winter predicted poor sleep-related profiles. Conclusions: Our generalizable predictive model identifies critical modifiable predictors of the association between sleep health and depression that could serve as potential targets for personalized interventions.

Background. UK clinical guidance recommends that structured risk prediction tools and risk stratification should not be used in self-harm, to predict suicide or determine who is offered treatment. Underpinning this position is the premise that routinely collected health data contain no useful predictive signal, which has received little direct scrutiny. Objective. To test whether routinely collected electronic health record data can distinguish groups at higher and lower risk of severe outcomes following paracetamol overdose. Methods. We analysed 4,095 adults presenting to NHS Lothian emergency departments with paracetamol overdose (2017-2023). Elastic-net logistic regression was fitted to 37 routinely collected electronic health record features to predict a composite of death or mental health inpatient admission at 0-7, 8-30 and 31-365 days following attendance, evaluated on a held-out 20% test set with bootstrapping. Findings. Events occurred in 5.5% of patients at 0-7 days, 2.0% at 8-30 days and 7.9% at 31-365 days, dominated by mental health admission. Bootstrap AUROC 95% confidence intervals lay above 0.5 in every window (0.65-0.82, 0.63-0.90, 0.71-0.85): models ranked patients better than chance. Calibration slopes (1.04, 1.14, 1.07) were close to one. Ranking drew primarily on mental health-related features. Conclusions. Routinely collected health data carried predictive signal for severe outcomes after paracetamol overdose, although discrimination fell short of what is needed for individual-level clinical use. Clinical implications. These models are not proposed for clinical deployment; however, treating risk prediction as a settled question will redirect research efforts, potentially excluding this patient population from machine learning advances driving improvements in care in other medical specialties.

Background Individuals with severe mental illness (SMI), including schizophrenia spectrum disorders (SSD) and bipolar disorder (BD), have been shown to have an elevated risk of violent perpetration. However, no population-wide study has systematically examined how this risk varies across psychiatric comorbidity patterns and specific violent crime types. Methods Using the first nationwide Norwegian registry linkage comprising mental health and crime data, we included 3,612,215 individuals aged 15-79 years living in Norway on Jan 1, 2008, and followed them until Dec 31, 2022. We estimated absolute and relative risks (RRs) of violent offending overall and by specific violent crimes among individuals with SSD and BD. To capture clinically relevant comorbidity patterns, we included substance use disorders (SUD), common personality disorders (PD), and hyperkinetic disorders (ADHD). RR models were adjusted first for sex and age, and subsequently for co-occurring mental disorders. Findings At the population level, individuals with SMI accounted for a minority of violent offenders (SSD: 8.7%; BD: 4.6%), whereas SUD was present among a substantially larger proportion (36.8%). Absolute risk of violent offending increased markedly with psychiatric comorbidity, from e.g., 5.0% among individuals with SSD alone to 43.9% for SSD combined with SUD and PD. Compared with the remaining general population, the RR of violent offending for SSD decreased from 6.58 (95% CI 6.4-6.8, adjusted for sex and age), to 2.0 (2.0-2.1) after further adjustment for other mental disorders. Similar attenuation patterns were observed across specific violent crime types, although varying in magnitude. In contrast to SMI, elevated risks associated with SUD remained substantial after full adjustment across most crime categories. Interpretation The association between SMI and violent offending is strongly influenced by psychiatric comorbidity, particularly SUD, and varies across crime types. Our findings underscore the importance of identifying and treating co-occurring mental disorders and substance use, both in the clinical management of SMI and in population-level violence prevention strategies.

Background Functional neurological disorder (FND), one of the most common neurological conditions, affects women almost twice as frequently as men. The reasons for this are unknown, and there has been minimal research into how physiological and pathological features of women's health interact with symptoms of FND. Methods We conducted an online survey assessing the effect of several aspects of women's health with the severity of symptoms of FND. Results 484 people completed the survey. Among the 223 who had regular or fairly regular menstrual cycles, a strong difference across the menstrual cycle was seen, with symptoms at their best in the follicular phase, worsening in the luteal phase, and worst in the pre-menstrual period and the menses. This effect was not moderated by a proxy measure of pre-menstrual dysphoric disorder (PMDD). Participants who were taking the combined oral contraceptive (COC, n=43) and progesterone-based contraception (n=80) were more likely to report symptom improvement from starting the medication than worsening. When compared to menstruating participants who were not taking the COC, participants taking the COC reported less worsening in their symptoms of FND in the luteal, pre-menstrual, and menstrual phases. Of the 99 women who had passed menopause since developing FND, 76% reported worsening of their FND symptoms after menopause. Discussion This study demonstrates interactions between several aspects of women's health and symptoms of FND. The observed pattern of symptom fluctuation across hormonal states suggests a potential modulatory role of oestrogen, warranting further targeted investigation.

Introduction: Group interpersonal psychotherapy (IPT-G) can expand access to depression care, but assessment conditions may influence outcomes. This pilot cluster-randomized trial was designed to refine outcome-measurement procedures and generate preliminary effect estimates to inform a larger trial. We evaluated a six-week model, examining associations between follow-up assessment conditions and depressive symptoms. Methods: In Mayuge, Uganda, female participants aged [&ge;]13 years with Patient Health Questionnaire-9 (PHQ-9) scores [&ge;]10 were randomized by village to IPT-G or enhanced treatment as usual. Primary outcome was the PHQ-9 score. Assessments occurred at baseline, two weeks and three months post-treatment. During early two-week follow-up, therapy facilitators remained visible near interview locations while mobilizing participants; thereafter, they left before subsequent interviews. At three months, interviews were conducted independently and participants were randomly assigned to receive a prompt emphasizing confidentiality, accurate reporting and that incentives were not contingent on responses. We examined associations between these two conditions and PHQ-9 scores. Results: Of 292 randomized participants, 263 provided three-month data. Mean PHQ-9 scores were lower in intervention than control participants at two weeks (1.73 versus 15.14; mean difference [MD] -13.41, 95% confidence interval [CI] -16.10 to -10.71) and three months (3.19 versus 10.97; MD -7.78, 95% CI -9.66 to -5.90; both p<0.001). Among intervention participants, prior assessment without facilitators and receipt of the confidentiality and honest-reporting prompt were jointly associated with 4.41-point higher PHQ-9 scores versus the reference condition (95% CI 2.37 to 6.45; p<0.001). In exploratory sensitivity analysis, an intervention subgroup exposed to both conditions had lower three-month PHQ-9 scores than controls (MD -5.19, 95% CI -7.39 to -2.99; p<0.001). Conclusions: Six-week IPT-G was associated with significant symptom reductions, but follow-up procedures influenced the apparent benefit, highlighting the need for independent outcome assessment in community-delivered psychological intervention trials. Trial registration: Pan African Clinical Trials Registry, PACTR202606549854263; retrospectively registered.

Background. Depression affects an estimated 332 million people worldwide and is a leading cause of disability, with up to 80% of major depressive episodes preceded by an identifiable adverse life event [17,18]. First-line treatments target symptoms rather than the precipitating event and are resource-intensive: standard CBT averages roughly 12 sessions, and antidepressant discontinuation carries relapse rates near 35% at six months [8]. These limitations create a clear rationale for brief, structured interventions that address the cognitive and somatic sequelae of adverse life events directly. Painhunting therapy is one such intervention, in which each session targets a discrete adverse event through a structured incident-processing procedure. Methods. We conducted a two-arm, parallel-group, single-site randomised controlled trial comparing Painhunting therapy (Arm A, immediate; n=42) with a waitlist control (Arm B, delayed; n=42) in adults with PHQ-9 >= 9 and active psychological distress related to an adverse life event. After the primary endpoint at T2 (approximately two weeks post-randomisation), Arm B crossed over to active treatment, with T3 as the post-crossover endpoint at approximately four weeks. The primary outcome was PHQ-9 at T2 (between-arm contrast); secondary outcomes were ICG, GAD-7, WHO-DAS 2.0 (12-item), and the Global Impression of Change (GIC). Pre-specified analyses included intention-to-treat, per-protocol, and single-exclusion sensitivity populations. Results. Eighty-four participants were randomised (198 applications, 134 completed screening questionnaire, 119 passed psychometric screening). At T2, mean PHQ-9 was 2.32 (SD 2.59) in Arm A and 16.56 (SD 6.76) in Arm B, yielding an ITT between-arm Cohen d = 2.78 (95% CI 2.19-3.76, p < 0.001). Within-arm paired reductions during each arm's active-treatment window reproduced this magnitude (Arm A T0 to T2 change 14.71, Morris d = 2.80; Arm B T2 to T3 change 14.19, Morris d = 2.77, eligible n=26). Treatment gains were durable at the T4 follow-up (week 8). Aligning each arm to its own end-of-treatment timepoint, the off-treatment drift to week 8 was almost identical between arms: Arm A rose 0.78 points from T2 to T4 (2.19 to 2.97, n=37) and Arm B rose 1.59 points from T3 to T4 (4.74 to 6.33, n=27), the latter falling to 0.77 points once a single documented relapse case (R59) is excluded (4.81 to 5.58, n=26). This small off-treatment rebound then stabilised rather than continuing: Arm A was essentially unchanged from T3 to T4 (change +0.05), with concordant maintenance on ICG, GAD-7, and WHO-DAS. At T4, 68% of Arm A and 41% of Arm B remained in remission (PHQ-9 < 5). Secondary measures (ICG, GAD-7, WHO-DAS) moved in the same direction and to comparable magnitude at every timepoint. The waitlist window in Arm B showed essentially no change on any measure (PHQ-9 change 0.22, p = 0.81). Sensitivity analyses excluding six sub-threshold T2 cases, the single treated-in-error case (R82), the R59 relapse case, and one late T2 submitter left all conclusions unchanged. Conclusions. Painhunting therapy produced large and statistically robust reductions in depression, complicated grief, anxiety, and functional disability over a brief course of three to four sessions, with effect sizes substantially exceeding benchmarks reported for established first-line psychotherapies including CBT and EMDR. Critically, these gains persisted at the week-8 follow-up: depression scores in the immediate-treatment arm were essentially unchanged from four weeks to eight weeks post-randomisation, indicating that the benefit reflects durable change rather than a transient post-session dip. Treatment-window concordance between arms, durability of gains at one month off-treatment, and the flat waitlist trajectory together strengthen the evidence for genuine efficacy rather than spontaneous remission. Baseline covariates including therapeutic alliance, treatment expectancy, self-efficacy, age, and sex showed near-zero associations with outcome, reducing the plausibility of allegiance bias or expectancy effects as primary drivers. The differential retention between arms (88% vs 64% at T3) is attributable to the waitlist design and is discussed as a limitation. These findings support proceeding to a confirmatory active-comparator trial against manualized CBT. Trial registration: ClinicalTrials.gov NCT07490691, prospectively registered.

One-to-one peer support is widely used in mental health services, but the components associated with better outcomes remain unclear. We systematically reviewed randomised controlled trials and conducted additive component network meta-analyses to identify which components of one-to-one peer support worker interventions were associated with outcomes for adults using mental health services. CINAHL Ultimate, Embase, MEDLINE, PsycINFO, CENTRAL, ClinicalTrials.gov and ISRCTN were searched, supplemented by citation tracking, previous reviews and expert consultation. Interventions were coded for seven components: Training and development, Maintaining peer support worker wellbeing, Relationship-building, Social support, Emotional support, Practical support and Cultural adaptation. The review followed PRISMA-NMA reporting guidance and was registered with PROSPERO (CRD42022355291). Thirty-six trials randomised 6,645 participants across nine countries. Only quality of life and recovery yielded estimable component effects at one or more follow-up points. For quality of life, Practical support had a positive incremental estimate at 3 months (standardised mean difference 0.52, 95% confidence interval 0.17 to 0.87); no component showed clear evidence of benefit at 6 months; and at 12 months Social support had a positive estimate (1.57, 0.12 to 3.01), whereas Maintaining peer support worker wellbeing had a negative estimate (-1.66, -3.05 to -0.28). These estimates were not consistent across follow-up points. For recovery, Relationship-building had positive estimates at 6 months (0.90, 0.03 to 1.78) and 12 months (0.50, 0.29 to 0.72). Networks were sparse and often disconnected, and additivity could not be tested in disconnected networks. Current trials do not permit definitive prioritisation of peer-support components. Relationship-building was the most consistent candidate component, but all findings remain provisional. Future trials should prospectively specify, manipulate and measure component delivery.

ABSTRACT Objective To assess the comparative efficacy and acceptability of cognitive behavioural therapy for insomnia (CBT-I), its abbreviated versions and control conditions. Design Systematic review and network meta-analysis. Methods Screening, data extraction, coding, and risk of bias assessment were performed independently and in duplicate. Frequentist, random-effects network meta-analyses estimated odds ratios (ORs) or mean differences with 95% confidence intervals (CIs). The primary outcome was insomnia remission post-treatment. Secondary outcomes included dropout and subjective sleep continuity measures. Quality of the evidence for each arm was graded using the confidence in network meta-analysis (CINeMA). Data sources We searched MEDLINE, Embase, PsycINFO and Cochrane CENTRAL from inception to December 15, 2025, with a medical information specialist. Eligibility criteria for selecting studies Randomized controlled trials (RCTs) comparing CBT-I and its abbreviated versions with each other or with control conditions, in adults with insomnia, with or without comorbidities. To reduce clinical heterogeneity related to treatment intensity and adherence, we restricted inclusion to in-person delivery. Results We identified 11,379 records and included 77 RCTs (5,731 participants; mean age 52.2 years; 3,473 female). CBT-I (number of arms k = 53; number of participants n = 2,002), sleep restriction and stimulus control therapy (SRT+SCT; k = 16; n = 549), sleep restriction therapy (SRT; k = 5; n = 196) and stimulus control therapy (SCT; k = 7; n = 144) were associated with higher remission than sleep hygiene, relaxation therapy and other control conditions. These interventions were also effective in improving subjective sleep continuity measures. Cognitive therapy for insomnia (CT-I) was more beneficial than relaxation therapy. Dropout did not differ meaningfully between interventions and controls. Confidence in evidence was moderate for CBT-I, low for SRT&SCT and SRT, very low for SCT. Given the weighted mean proportion of insomnia remission among sleep hygiene arms of 20%, CBT-I probably leads to a remission rate of 41% (95% CI, 34%; 48%), SRT&SCT may lead to a remission rate of 40% (30%; 52%), SCT 43% (25%; 63%), and SRT 41% (26%; 57%). Conclusions CBT-I doubles the absolute insomnia remission compared with sleep hygiene, and its abbreviated behavioural therapies, namely, SRT+SCT, SCT and SRT may offer similar benefits with lower resource requirements, but evidence is less certain. CT-I needs further investigations. Relaxation therapy was inferior to these therapies. Implementation decisions should consider resource requirements and evidence certainty. Systematic review registration The Open Science Framework, https://osf.io/z48r2/.

Objective Psychosis spectrum symptoms (PSS) are common among children and youth. These symptoms may be clinically significant as studies indicate a heightened risk of mental health disorders, in general, as well as psychotic disorders, specifically, in youth that endorse PSS. This systematic review and meta-analysis investigates the longitudinal association between PSS in children and youth and subsequent mental health diagnosis. Methods A comprehensive search of Ovid Medline, PsycINFO, and EMBASE databases was conducted to identify longitudinal studies that: (i) assess PSS at a baseline timepoint, (ii) in individuals under 25 years, and (iii) assess mental health disorder diagnosis using a structured assessment at a later time point in the same sample. We conducted a meta-analysis and calculated pooled odds ratios (ORs) for mental health and psychotic disorders using random-effects models. Post-hoc meta-regressions were performed to examine the influence of a number of moderators on the relationship between earlier recorded PSS and subsequent mental health disorders or psychotic disorders. Results The search yielded 41 eligible studies of which 25 were included in the meta-analysis. Most included studies assessed PSS using brief self-report measures and recruited their samples from clinical or community settings. Among children and youth without an identified mental health diagnosis at baseline assessment, baseline PSS were associated with a 2-fold (OR = 2.07, CI = 1.61 - 2.66, I2 = 86.92%, p < 0.0001) increased risk of meeting diagnostic criteria for subsequent mental health disorder diagnosis and a 3-fold increased risk (OR = 3.11, CI = 2.11 - 4.58, (I2 = 60.93%, p < 0.0090) of meeting diagnostic criteria for a subsequent psychotic disorder diagnosis with a minimum 1 year follow-up time from baseline assessment. Meta-regression analysis indicated that study quality and sample size explained a substantial proportion of between-study heterogeneity for psychotic disorder outcomes. Conclusions Our results suggest that administration of simple self-report measures of PSS in both clinical and community settings may be helpful to identify children and youth at higher risk of subsequently meeting criteria for a mental disorder generally, and for a severe mental illness (i.e., psychotic disorder), specifically. Future longitudinal studies should focus on improving study design characteristics to increase confidence in identified longitudinal associations. The results of our work suggests that integration of self-report measures of PSS may be useful in a variety of settings to identify youth at increased risk of subsequent mental illness.

Although romantic partners tend to resemble each other on many characteristics, the geographical processes underlying partner similarities remain poorly understood. Using Finnish nationwide registry data from cohabiting or married partners (N = 1,500,204 couples; partnerships were formed between 1990-2023), we examined regional differences in partner similarity in mental disorders, educational attainment, and adolescent school performance. We also analysed geographical variation in partner similarity within three major cities. Accounting for local demographic composition of potential partners attenuated the partner similarity from r=0.43 to r=0.34 for highest obtained educational attainment, but increased partner similarity in any mental disorders from r=.40 to r=.42. In urban municipalities partners were more similar in educational attainment, but less in mental disorders, compared to more rural regions. We found no clear within-city variation in partner similarity. These findings highlight the role regional demographic composition plays in partnership formation and suggest different partnering dynamics depending on societal organization.

Importance Anxiety and depression frequently co occur and show developmentally patterned co-development from childhood to adolescence. Adult psychiatric outcomes vary according to the timing, sequencing, and persistence of early symptoms, yet it remains unclear whether patterns of co development are comparable across high income and low and middle income country contexts. Objective Examine joint developmental trajectories of anxiety and depression from childhood to adolescence and their associations with anxiety and depression diagnoses in young adulthood. Design, Setting and Participants Population based prospective cohort studies in the UK (Avon Longitudinal Study of Parents and Children [ALSPAC], N=9,586) and Brazil (Pelotas 2004 Birth Cohort, N=3,815). Main Outcomes and Measures Trajectories were derived using parallel process latent growth models and latent class growth analyses of anxiety and depression using the Development and Well Being Assessment at early childhood (6-7 years), middle childhood (10-11 years), and adolescence (13-15 years). Diagnoses of anxiety and depression at 18 years were assessed via the Clinical Interview Schedule (ALSPAC) and the Mini International Neuropsychiatric Interview (Pelotas). Results Prevalence of anxiety and depression from early childhood to adolescence was similar across cohorts. Co-development was stronger in ALSPAC, with modest increases in both conditions, whereas in Pelotas, anxiety increased rapidly while depression showed little average change. In both cohorts, four trajectory classes were identified: stable-low (ALSPAC, 41%; Pelotas, 54%), increasing (31%; 28%), decreasing (23%; 15%), and persistent-high anxiety/increasing depression (5%; 3%). Compared with the stable-low class, youth in the increasing and persistent-high classes had elevated odds of depression (ALSPAC: OR=2.0 [95% CI, 1.4-2.8] and 4.2 [2.6-6.7]; Pelotas: 2.2 [1.5-3.3] and 2.9 [1.4-6.0]) and anxiety in young adulthood (ALSPAC: 1.6 [1.2-2.2] and 4.8 [3.2-7.0]; Pelotas: 1.7 [1.2-2.6] and 2.9 [1.5-5.8]). No increased risk was observed in the decreasing class. Conclusions and Relevance Patterns of anxiety and depression co development were comparable across the UK and Brazil, suggesting shared developmental pathways. However, more rapid increases in anxiety among Brazilian youth may reflect context specific risk factors. Persistence or emergence beyond early childhood was critical for identifying later diagnostic risk in both settings, highlighting the importance of early monitoring and intervention.

Stroboscopic light stimulation (SLS) is a candidate non-pharmacological intervention that induces transient visual and affective experiences, with potential application in depression. Before efficacy testing, clinical development requires safety, tolerability and feasibility data. We report a staged, single-site programme in adults reporting depressive symptoms. Work Package (WP) 1 tested 11 SLS parameter sets for safety and tolerability. An interim bridge study assessed whether a low-phenomenology SLS control reduced subjective visual effects while preserving session context. WP2 randomised 84 participants to four weekly supervised 31-minute sessions of the intervention or a low-phenomenology control. In WP1, 31 participants were analysed; no severe adverse reactions occurred, mean discomfort was low (0.49/10), and the highest session-level upper 80% confidence limit was 1.13/10, well below the prespecified threshold. The interim study supported experiential separation between intervention and control. In WP2, endpoint data were available for 70/84 participants (83.3%): 39/42 in the intervention arm and 31/42 in the control arm. Overall retention met the criterion, but lower control-arm retention remains a design issue; protocol adherence was high, discomfort remained low, and no serious SLS-attributable adverse events occurred. Exploratory depressive-symptom changes suggested a possible BDI-II signal, but do not establish efficacy. Supervised SLS met key safety, tolerability, and feasibility criteria, and a lower visual-phenomenology active control can be carried forward, while masking and comparator credibility remain to be established. The next step is a diagnostically defined, CTU-governed Phase 2a feasibility trial that pre-registers a locked protocol and tests masking, credibility, retention and endpoint precision.